Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: A 3-year open-label clinical study

Journal of Clinical Psychiatry

Volumn 73, Issue 4, 2012, Pages

  Emsley, Robin ^a   Oosthuizen, Petrus P ^a   Koen, Liezl ^a   Niehaus, Dana J H ^a   Martinez, Guadalupe ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Janssen Cilag EMEA Belgium   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DSM-IV; FEMALE; HUMAN; MALE; MENTAL DISEASE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RECURRENT DISEASE; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOM; TREATMENT DURATION;

EID: 84860561502     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07138     Document Type: Article

References (47)

1. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156(4):544-549. PubMed (Pubitemid 29162974)
2. McEvoy JP, Scheifler PL, Frances A, eds. Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry. 1999; 60(suppl 11):1-80.
3. Lehman AF, Lieberman JA, Dixon LB, et al American Psychiatric Association Steering Committee on Practice Guidelines. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry. 2004;161(suppl 2):1-56. PubMed
4. The International Psychopharmacology Algorithm Project (IPAP). IPAP Algorithms List. 2006. http://www.ipap.org/algorithms.php. Verified February 2, 2012.
5. National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (update) (NICE). National Clinical Practice Guideline Number 82. London, UK: The National Institute for Health and Clinical Excellence; 2009.
6. Moller HJ, von Ziersen D. Course and outcome of schizophrenia. In: Hirsh SR, Weinberger DR, eds. Schizophrenia. Oxford, UK: Blackwell; 1995:106-127.
7. Perkins DO, Gu H, Weiden PJ, et al Comparison of Atypicals in First Episode Study Group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69(1):106-113. doi:10.408/JCP.v69n014 PubMed (Pubitemid 351282003)
8. Wyatt RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997;23(1):3-9. PubMed (Pubitemid 27087902)
9. Lieberman JA, Alvir JM, Koreen A, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996; 14(suppl 3):13S-21S. doi:10.1016/0893-13X(95)020-W PubMed
10. Carpenter WT Jr, Heinrichs DW. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull. 1983;9(4): 533-542. PubMed (Pubitemid 14219104)
11. Carpenter WT Jr, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry. 1990;147(9):1138-1148. PubMed (Pubitemid 20275365)
12. Buchanan RW, Kreyenbuhl J, Kelly DL, et al Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93. doi:10.1093/schbul/sbp16 PubMed
13. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52(3):173-188. PubMed
14. Kane JM, Rifkin A, Quitkin F, et al. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry. 1982;39(1):70-73. PubMed (Pubitemid 12163378)
15. Crow TJ, MacMillan JF, Johnson AL, et al. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148(2): 120-127. doi:10.192/bjp.148.2.120 PubMed (Pubitemid 16158512)
16. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158(11):1835-1842. doi:10.176/api.ajp.158. 1.1835 PubMed (Pubitemid 33054776)
17. Wunderink L, Nienhuis FJ, Sytema S, et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654-661. doi:10.408/JCP. v68n0502 PubMed (Pubitemid 46841847)
18. Gaebel W, Riesbeck M, Wölwer W, et al German Study Group on First-Episode Schizophrenia. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome - based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011;72(2):205-218. doi:10.408/JCP.09m05459yel PubMed
19. Chen EY, Hui CL, Lam MM, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ. 2010;341:c4024. doi:10.136/bmj.c4024 PubMed
20. Emsley R, Medori R, Koen L, et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008;28(2):210-213. doi:10.1097/JCP.0b013e318167269d PubMed (Pubitemid 351419182)
21. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 1994.
22. Carpenter WT Jr, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry. 1997; 54(5):401-407. PubMed (Pubitemid 27198203)
23. Viguera AC, Baldessarini RJ, Hegarty JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54(1):49-55. PubMed (Pubitemid 27044698)
24. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8(1):27-36. doi:10.1017/S14614570404924 PubMed (Pubitemid 40388811)
25. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
26. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
27. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;(22):39-44. PubMed (Pubitemid 23355888)
28. Ware JE Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-233. doi:10.1097/05650-196030-03 PubMed (Pubitemid 126433231)
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:760-761.
30. Rabinowitz J, Levine SZ, Medori R, et al. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness. Schizophr Res. 2008;100(1-3):359-360. doi:10.1016/j.schres.207.10.021 PubMed
31. Csernansky JG, Mahmoud R, Brenner R; Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16-22. doi:10.1056/NEJMoa02028 PubMed (Pubitemid 34438915)
32. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449. doi:10.176/api.ajp.162.3.41 PubMed (Pubitemid 40343909)
33. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546. doi:10.408/JCP.v58n1205 PubMed (Pubitemid 28100274)
34. Subotnik KL, Nuechterlein KH. Prodromal signs and symptoms of schizophrenic relapse. J Abnorm Psychol. 1988;97(4):405-412. doi:10.1037/021-843X.97.4.405 PubMed (Pubitemid 18266364)
35. Henmi Y. Prodromal symptoms of relapse in schizophrenic outpatients: retrospective and prospective study. Jpn J Psychiatry Neurol. 1993;47(4): 753-775. PubMed (Pubitemid 24087691)
36. Tarrier N, Barrowclough C, Bamrah JS. Prodromal signs of relapse in schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1991;26(4):157-161. PubMed
37. Herz MI, Melville C. Relapse in schizophrenia. Am J Psychiatry. 1980; 137(7):801-805. PubMed (Pubitemid 10085116)
38. Birchwood M, Smith J, Macmillan F, et al. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med. 1989;19(3):649-656. doi:10.1017/S032917024247 PubMed (Pubitemid 19243711)
39. Norman RM, Malla AK. Prodromal symptoms of relapse in schizophrenia: a review. Schizophr Bull. 1995;21(4):527-539. PubMed
40. Gaebel W, Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res. 2007;95(1-3): 19-29. doi:10.1016/j.schres.207.06.016 PubMed (Pubitemid 47313652)
41. Gaebel W, Frick U, Köpcke W, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry Suppl. 1993;(21):8-12. PubMed (Pubitemid 23271363)
42. Gleeson JF, Rawlings D, Jackson HJ, et al. Early warning signs of relapse following a first episode of psychosis. Schizophr Res. 2005;80(1):107-111. doi:10.1016/j.schres.205.07.019 PubMed (Pubitemid 41587468)
43. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996;22(2):353-370. PubMed (Pubitemid 26174579)
44. Lieberman JA, Alvir J, Geisler S, et al. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology. 1994;11(2):107-118. PubMed (Pubitemid 24334066)
45. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247. doi:10.101/archpsyc.56.3.241 PubMed (Pubitemid 29125132)
46. Buchanan RW, Kirkpatrick B, Summerfelt A, et al. Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiatry. 1992;32(1): 72-78. doi:10.1016/06-323(92)90143-N PubMed
47. Üçok A, Polat A, Çakir S, et al. One year outcome in first episode schizophrenia: predictors of relapse. Eur Arch Psychiatry Clin Neurosci. 2006;256(1):37-43. doi:10.107/s0406-05-0598-2 PubMed (Pubitemid 43288242)